Kamada Ltd（KMDA）の株式分析KMDAKamada Ltd

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kamada Ltd appears to be a good buy right now due to its recent FDA approval for a new laboratory, which enhances its operational capabilities and positions it well in the growing rabies immunoglobulin market. The current price of $7.77 is below the Fibonacci R1 level of $7.94, suggesting potential upside. Additionally, the company has shown a strong gross margin of 40.91% in Q2 2026, indicating solid profitability. However, a key risk is the recent Q1 earnings miss, where EPS was $0.07, falling short of expectations by $0.05, which could impact investor sentiment in the short term.

1 analysts cover KMDA: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.00.